|
|||||
|
|
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial |
|
| Authors: | João Sérgio Neves MD Francisco Vasques-Nóvoa MD Marta Borges-Canha MD Ana Rita Leite MD Abhinav Sharma MD Davide Carvalho MD Milton Packer MD Faiez Zannad MD Adelino Leite-Moreira MD João Pedro Ferreira MD |
| Affiliation: | 1. Cardiovascular R&D Centre—UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal;2. Cardiovascular R&D Centre—UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal Department of Internal Medicine, Centro Hospitalar Universitário de São João, Porto, Portugal;3. Division of Cardiology, DREAM-CV Lab, McGill University Health Centre, Montreal, Canada;4. Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal;5. Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA;6. Université de Lorraine, Inserm, Centre d'Investigations Cliniques, Plurithématique 14-33, and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France;7. Cardiovascular R&D Centre—UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal Department of Cardiothoracic Surgery, Centro Hospitalar Universitário São João, Porto, Portugal |
| Abstract: | |
| Keywords: | adverse events arrhythmia GLP-1 receptor agonists heart failure hospitalizations heart failure with reduced ejection fraction liraglutide |